BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT
VANCOUVER, BC, March 22, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “the Company”) announces that it intends to complete a non-brokered private placement (the “Private Placement”) consisting of up to 15,384,615 units (“Units”) at a price of $0.065 per Unit for total gross proceeds of up to CAD$1,000,000, before deducting any offering-related expenses. Each Unit consists of one common share (a “Common Share”) and one whole Common Share purchase warrant (a “Warrant”). Each Warrant is exercisable for one additional Common Share at an exercise price of $0.15 for a period of 24 months.
Related news for (BVAXF)
- BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
- BioVaxys Technology Corp. Granted Management Cease Trade Order
- Exploring New Frontiers in Food Allergy Treatments: Market Set for $14B Growth
- Biovaxys Signs Binding Letter of Intent to Develop DPX™-Based Vaccines for Life Threatening Food Allergies
- BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT AND DEBT SETTLEMENT